TSE:VRX - Valeant Pharmaceuticals Intl Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$32.19 -0.67 (-2.04 %)
(As of 06/22/2018 04:00 PM ET)
Previous CloseC$32.86
Today's RangeC$31.78 - C$32.56
52-Week RangeC$14.01 - C$36.02
Volume1.16 million shs
Average Volume1.44 million shs
Market CapitalizationC$7.69 billion
P/E RatioN/A
Dividend YieldN/A
Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%


Outstanding Shares349,299,000

Valeant Pharmaceuticals Intl (TSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals Intl's earnings last quarter?

Valeant Pharmaceuticals Intl Inc (TSE:VRX) issued its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $0.27. The specialty pharmaceutical company had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.54 billion. Valeant Pharmaceuticals Intl had a return on equity of 112.73% and a net margin of 58.58%. View Valeant Pharmaceuticals Intl's Earnings History.

When is Valeant Pharmaceuticals Intl's next earnings date?

Valeant Pharmaceuticals Intl is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Valeant Pharmaceuticals Intl.

What price target have analysts set for VRX?

3 Wall Street analysts have issued 1-year price objectives for Valeant Pharmaceuticals Intl's stock. Their forecasts range from C$23.00 to C$25.50. On average, they expect Valeant Pharmaceuticals Intl's share price to reach C$24.25 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. J. Michael Pearson, Former Chief Exec. Officer (Age 59)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 46)

Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?

Press coverage about VRX stock has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Valeant Pharmaceuticals Intl earned a news sentiment score of 0.04 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 45.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Valeant Pharmaceuticals Intl?

Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals Intl's stock price today?

One share of VRX stock can currently be purchased for approximately C$32.19.

How big of a company is Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl has a market capitalization of C$7.69 billion.

How can I contact Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.

MarketBeat Community Rating for Valeant Pharmaceuticals Intl (VRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.